JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, A. K.
Right arrow Articles by Joseph, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, A. K.
Right arrow Articles by Joseph, W. S.

Journal of the American Podiatric Medical Association, Vol 90, Issue 10 495-501, Copyright © 2000 by American Podiatric Medical Association

JOURNAL ARTICLE

Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States

AK Gupta and WS Joseph
Department of Medicine, Sunnybrook and Women's College Health Sciences Center (Sunnybrook Site), Toronto, Ontario, Canada. agupta@execulink.com

Ciclopirox 8% nail lacquer has recently become the first topical antifungal agent to be approved by the US Food and Drug Administration for the treatment of onychomycosis. This article reviews the results of the two pivotal clinical trials of this drug that have been performed in the United States as well as those that have been carried out in other countries. The two US studies were both double-blind, vehicle-controlled, parallel-group, multicenter studies designed to determine the efficacy and safety of ciclopirox nail lacquer in the treatment of mild-to-moderate onychomycosis of the toenails caused by dermatophytes. The combined results show a 34% mycologic cure rate, as compared with 10% for the placebo. Data from the ten studies conducted worldwide show a meta-analytic mean (+/- SE) mycologic cure rate of 52.6% +/- 4.2%. As expected for a topical agent, ciclopirox nail lacquer was found to be extremely safe, with mild, transient irritation at the site of application reported as the most common adverse event. Ciclopirox nail lacquer may also have potential for use in combination or adjunctive therapy. Further studies will help to better position this agent for the treatment of this widespread podiatric condition.


This article has been cited by other articles:


Home page
 J. Am. Podiatr. Med. Assoc.Home page
M. A. Brenner, L. B. Harkless, R. W. Mendicino, and J. C. Page
Ciclopirox 8% Nail Lacquer Topical Solution for the Treatment of Onychomycosis in Patients with Diabetes: A Multicenter, Open-Label Study
J Am Podiatr Med Assoc, May 1, 2007; 97(3): 195 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
J. Porthouse and D. J. Torgerson
The Need for Randomized Controlled Trials in Podiatric Medical Research
J Am Podiatr Med Assoc, May 1, 2004; 94(3): 221 - 228.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Podiatric Medical Association.